A new series of azo compounds of 4,6-dipropanoylresorcinol were synthesized and molecular docking studies were performed on newly synthesized six compounds on the active site of EGFR to study the binding mode of these analogs. ADME properties of all the newly synthesized six compounds were calculated by Qik Prop v3. 7. All the designed compounds were found to exhibit lead like properties from the calculated ADME properties. We worked with successful insilico approaches like molecular docking and pharmacokinetic properties. As a result, we found all the six azo derivatives are exceedingly capable of acting as antagonist for EGFR.